Phosphodiesterase 4 Inhibition as a Therapeutic Target for Alcoholic Liver Disease: From Bedside to Bench

Walter E. Rodriguez, Banrida Wahlang, Yali Wang, Jingwen Zhang, Manicka V. Vadhanam, Swati Joshi‐Barve, Philip Bauer, Robert Cannon, Ali Reza Ahmadi, Zhaoli Sun, Andrew Cameron, Shirish Barve, Claudio Maldonado, Craig McClain, Leila Gobejishvili – 13 May 2019 – Alcoholic liver disease (ALD) is a major cause of liver‐related mortality. There is still no US Food and Drug Administration–approved therapy for ALD, and therefore, identifying therapeutic targets is needed.

Hepatocyte Deletion of Triglyceride‐Synthesis Enzyme Acyl CoA: Diacylglycerol Acyltransferase 2 Reduces Steatosis Without Increasing Inflammation or Fibrosis in Mice

Nina L. Gluchowski, Katlyn R. Gabriel, Chandramohan Chitraju, Roderick T. Bronson, Niklas Mejhert, Sebastian Boland, Kun Wang, Zon Weng Lai, Robert V. Farese, Tobias C. Walther – 13 May 2019 – Nonalcoholic fatty liver disease (NAFLD) is characterized by excess lipid accumulation in hepatocytes and represents a huge public health problem owing to its propensity to progress to nonalcoholic steatohepatitis, fibrosis, and liver failure. The lipids stored in hepatic steatosis (HS) are primarily triglycerides (TGs) synthesized by two acyl‐CoA:diacylglycerol acyltransferase (DGAT) enzymes.

Dependency of Cholangiocarcinoma on Cyclin D–Dependent Kinase Activity

Gunya Sittithumcharee, Orawan Suppramote, Kulthida Vaeteewoottacharn, Chumphon Sirisuksakun, Supawan Jamnongsong, Phatthamon Laphanuwat, Monthira Suntiparpluacha, Arriya Matha, Porncheera Chusorn, Pongsakorn Buraphat, Chumpot Kakanaporn, Komgrid Charngkaew, Atit Silsirivanit, Krittiya Korphaisarn, Somchai Limsrichamrern, Pinpat Tripatara, Chawalit Pairojkul, Sopit Wongkham, Somponnat Sampattavanich, Seiji Okada, Siwanon Jirawatnotai – 11 May 2019 – Cholangiocarcinoma (CCA) is a bile duct cancer with a very poor prognosis.

Subscribe to